Company news
Optiscan Imaging Limited news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Extension of Time to Hold Annual General Meeting
November 19, 2026
Bell Potter Healthcare Conference Presentation
November 16, 2026
Optiscan Strengthens Board with Appointment of Russell Low
November 4, 2026
Notification of cessation of securities - OIL
November 3, 2026
Quarterly Activities/Appendix 4C Cash Flow Report
October 29, 2026
Quarterly Activities/Appendix 4C Cash Flow Report
October 29, 2026
Optiscan Lodges U.S. FDA 510(k) Submission for InVue
October 4, 2026
Optiscan Lodges U.S. FDA 510(k) Submission for InForm
October 1, 2026
Change of Director's Interest Notice
September 15, 2026
Notification of cessation of securities - OIL
September 15, 2026
Application for quotation of securities - OIL
September 15, 2026
Significant Milestone Reached in ACL Digital Pathology Study
September 9, 2026
Change of Director's Interest Notice
September 9, 2026
Application for quotation of securities - OIL
September 9, 2026
Application for quotation of securities - OIL
September 8, 2026
Change of Director's Interest Notice
September 8, 2026
Change of Director's Interest Notice
September 8, 2026
Optiscan Initiates Head and Neck Cancer Study in the US
August 31, 2026
Preliminary Final Report
August 24, 2026
Appendix 4G & Corporate Governance Statement
August 24, 2026
2026 Annual Report
August 24, 2026
Quarterly Activities/Appendix 4C Cash Flow Report
July 30, 2026
Optiscan Signs New Research Agreement for Breast Study
July 21, 2026
Head and Neck Study Progressing Ahead of Schedule
July 20, 2026
Optiscan Launches InSpecta Device for Veterinary Medicine
July 6, 2026
Halfway Mark Reached in Optiscan Breast Cancer Study
June 3, 2026
Second Anniversary of Optiscan and Mayo Clinic Agreement
May 31, 2026
Optiscan Receives $1.69m R&D Tax Refund
May 19, 2026
Optiscan Submits InSpecta FDA Dossier
March 30, 2026
Appendix 4D
February 24, 2026
Quarterly Activities/Appendix 4C Cash Flow Report
January 29, 2026
Optiscan Initiates Head & Neck Cancer Imaging Study
December 2, 2025
Optiscan Partners with ACL to Advance Digital Pathology
November 10, 2025
Appendix 4E - Preliminary Final Report
August 29, 2025
Entitlement Issue Prospectus
August 27, 2025
Optiscan Launches Entitlement Offer to Raise $17.75m
August 27, 2025
Optiscan Initiates Breast Cancer Study in Melbourne
June 30, 2025
Optiscan Signs Agreement with Long Grove Pharmaceuticals
June 22, 2025
Optiscan Reveals InSpecta Device for Veterinary Medicine
June 9, 2025
Optiscan Completes Cloud-based Telepathology Software MVP
May 26, 2025
Robotic Surgery Collaboration with Mayo Clinic Progresses
May 12, 2025
Optiscan Reveals InForm Imaging Device for Pathology
February 18, 2025
Optiscan Initiates GI Study in Germany with First Prototype
February 2, 2025
OIL December 2024 Quarterly Report and Appendix 4C
January 30, 2025
Optiscan receives $1.775m R&D Tax Refund
January 30, 2025
OIL Managing Director's Presentation & Chair's Address
November 21, 2024
Optiscan Signs Research Agreement with Minnesota Vet College
November 18, 2024
Optiscan Signs Agreement with Monash to Progress GI Scope
November 3, 2024
OIL September 2024 Quarterly Report and Appendix 4C
October 31, 2024
Appendix 4E Preliminary Final Report
August 30, 2024
Decks
The 5 newest of 38 decks. Every deck is listed under its year.
- Bell Potter Healthcare Conference (November 2026)
Conference · 11 slides · Nov 17, 2026
- Investor Presentation (December 2025)
Investor deck · 37 slides · Dec 4, 2025
- Shareholder Meeting (November 2025)
Shareholder meeting · 40 slides · Nov 14, 2025
- ASX SMIDcaps Conference, Sydney 2025
Conference · 22 slides · Sep 24, 2025
- Corporate Update (April 2025)
Corporate update · 26 slides · Apr 10, 2025